NCT05399654 - A Dose Escalation and Expansion Study of TAC-001 in Patients With Select Advanced or Metastatic Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 28, 2022

Primary Completion Date

January 27, 2026

Study Completion Date

May 19, 2026

Conditions

Advanced or Metastatic Solid Tumors

Interventions

DRUG

TAC-001

TAC-001 is a Toll-like Receptor Agonist Antibody Conjugate (TRAAC)

Trial Locations (12)

Clinical Site, Nedlands

Weill Cornell Medicine- NYU Clinical Cancer Center, New York

NEXT Oncology- Virginia, Fairfax

AdventHealth Cancer Institute, Orlando

Sarah Cannon Research Institute (SCRI)- Florida Cancer Specialists and Research Institute, LLC, Orlando

West Cancer Center & Research Institute, Germantown

NEXT Oncology, Irving

The University of Texas MD Anderson Cancer Center, Houston

University of Colorado, Aurora

Sarah Cannon Research Institute (SCRI)- Denver, Denver

University of Southern California (USC), Los Angeles

John Theurer Cancer Center, Hackensack